Peptide Half-Life and Stability: What DAC, PEG, Acetylation and Aib Actually Do

When people say "peptide stability" they are usually running together two distinct questions: how long the material stays chemically intact in its vial — a question of months at a given temperature — and how long the peptide survives once it is in a biological system, which is a question of minutes to days. Modifications like DAC, PEGylation, amidation, acetylation and D-amino-acid substitution are all aimed at the second question, and working out which enzyme or clearance route each one blocks is the fastest way to anticipate how an analogue will behave in your experiment. What follows distinguishes the two types of stability, walks through the four clearance mechanisms a peptide has to withstand, tabulates published half-lives for the molecules in our range, and works the decay arithmetic. Every figure quoted comes from published pharmacokinetic work on the reference compounds, not from measurements on the material we supply.

Circulating half-life and shelf life are separate clocks

Conflating the two produces mistakes in both directions. A molecule with a plasma half-life of one minute can be perfectly stable in a freezer for three years, and conversely a peptide engineered to circulate for a week is no more resistant to a freeze–thaw cycle than the unmodified sequence it came from.

Four routes by which peptides are cleared

1. Exopeptidases. These work inwards from the termini — carboxypeptidases at the C-terminal end, aminopeptidases at the N-terminal end — and capping the exposed end blocks them.
2. Endopeptidases, DPP-4 above all. Dipeptidyl peptidase-4 removes the first two amino acids from any peptide with proline or alanine at position 2 — a description covering GHRH, GIP, native GLP-1 and plenty of others. This single enzyme defines most of the design space that GHRH and incretin analogues occupy.
3. Renal filtration. The glomerulus lets molecules through freely below roughly 30–50 kDa, and essentially every research peptide is well under that, so unbound peptide is lost the first time blood passes through the kidney. There are only two ways around it: raise the apparent size beyond the cutoff, or attach the peptide to a large plasma protein.
4. Receptor-mediated uptake and hepatic clearance. An agonist is taken up along with the receptor it binds, which sets a floor on clearance that no chemical modification can remove.

What each modification achieves

Substituting position 2 to block DPP-4

DPP-4 cleaves native GLP-1 at position 2, which is why it survives only about 1.5–2 minutes in plasma. Replace that alanine with a non-standard residue — D-Ala in several GHRH analogues, or Aib (α-aminoisobutyric acid) in tirzepatide and semaglutide — and the enzyme no longer recognises its substrate. The same tactic appears in CJC-1295 without DAC: four substitutions on the GHRH(1-29) chain confer DPP-4 resistance and raise the reported half-life from the few minutes of native GHRH to somewhere around 30 minutes.

Binding albumin: DAC and fatty-acid acylation

Thirty minutes is still short. The next step is to tether the peptide to serum albumin, a protein of 66.5 kDa that is too big to pass the glomerulus and that itself lasts about 19 days. Two approaches dominate:

• DAC — the drug affinity complex, a maleimidoproprionyl group forming a covalent bond with the free thiol at albumin's cysteine-34. That is exactly why the reported half-life of CJC-1295 with DAC is measured in days rather than minutes, the trade-off being an exposure profile that is continuous instead of pulsatile — a difference that matters a great deal in growth-hormone research.
• Fatty-acid acylation — a C16 or C18 diacid, usually joined through a linker, which binds albumin reversibly without forming a covalent bond. This is the mechanism behind semaglutide's reported terminal half-life of roughly 165 hours, about a week, and liraglutide's of about 13 hours; the difference between them comes down mostly to the chain and linker chemistry.

PEGylation: purchasing bulk

A PEG chain does not make a peptide resistant to proteases — it makes it bulky and hard to grip. A polymer of 5–40 kDa raises the hydrodynamic radius above the glomerular cutoff and physically covers the sites where enzymes would cut. PEG-MGF is the clearest example: unmodified MGF is reported to disappear within minutes, while the attached PEG extends that into hours. The price is a lower receptor affinity per molecule, a heterogeneous preparation whenever the PEG itself is polydisperse, and a stated molecular weight dominated by polymer rather than peptide.

Capping the ends and using non-natural residues

• Acetylation of the N-terminus protects the free amine group from aminopeptidases and adds 42.04 Da — which is why TB-500 is supplied as Ac-LKKTETQ.
• Amidation of the C-terminus blocks carboxypeptidases, cancels a negative charge, and in many naturally occurring signalling peptides is a prerequisite for any receptor activity whatsoever.
• Combining both, as N-Acetyl Semax Amidate does, closes off a short sequence that would otherwise be eaten from either end.
• Cyclisation and D-amino acids give the backbone a shape that proteases, which evolved against L-amino-acid chains, cannot read. How all of this is written down is covered in how to read a peptide sequence.

Working through the decay arithmetic

Elimination follows first-order kinetics, so the proportion remaining after an interval t is 0.5 raised to the power (t ÷ half-life). Two implications are worth calculating explicitly:

1. Clearance. With a half-life of 30 minutes, two hours amounts to four half-lives, so 0.5⁴ — 6.25% — is left; by 3 hours, 6 half-lives have passed and 1.6% remains. Anything at this end of the scale has effectively disappeared within a single working day.
2. With a half-life of 7 days, two hours is only 0.0119 half-lives, leaving 99.2%. A sampling schedule designed for one of these molecules is useless for the other.
3. Steady state. Under repeated administration the plateau is approached after about five half-lives — roughly 2.5 hours for the 30-minute peptide, roughly 35 days for the 7-day one. Study length should be set by that number rather than by convenience.

What none of these modifications alters

Shelf life follows an entirely different chemistry. A rough guide derived from Arrhenius behaviour is that the rates of the relevant degradation pathways approximately double for each 10 °C rise in temperature, which explains why a freeze-dried vial rated in years at −20 °C may only be specified in weeks at 25 °C. An albumin-binding or PEGylated analogue gains nothing at all in this respect, since those modifications defend the molecule against enzymes and not against oxidation, hydrolysis or moisture finding its way in.

• Exclude water. Residual moisture drives most solid-state degradation, and opening a vial while it is still cold draws condensation onto the powder.
• Keep oxygen and light away. The residues that normally suffer first are tryptophan, cysteine and methionine.
• Minimise freeze–thaw cycles. Solutes concentrate at the advancing ice front and promote aggregation, so aliquot instead, as described in aliquoting peptide solutions.

The summary is simple: modify the molecule if you want to change what happens inside an organism, and control the storage conditions if you want to change what happens inside the vial. One will never do the other's job.